Healthcare - Oncology
Companies developing cancer therapeutics, diagnostics, and precision oncology tools
Immunotherapy & Immuno-Oncology78
Targeted Therapy & Precision Oncology95
Cell & Gene Therapy for Cancer35
Radiopharmaceuticals & ADCs11
Cancer Diagnostics & Biomarkers28
 LLY | Eli Lilly & Co. | Targeted Therapy & Precision Oncology | $1.0t | $1185.88 | -0.5% | 1.8M |
 JNJ | Johnson & Johnson | Immunotherapy & Immuno-Oncology | $0.6t | $259.31 | +1.1% | 3.7M |
 ABBV | ABBVIE INC. | Immunotherapy & Immuno-Oncology | $443.4b | $245.77 | +0.9% | 2.8M |
 MRK | Merck & Co., Inc. | Immunotherapy & Immuno-Oncology | $315.6b | $127.95 | +0.2% | 5.1M |
 AZN | AstraZeneca PLC | Immunotherapy & Immuno-Oncology | $263.1b | $161.23 | +0.2% | 3.5M |
 AMGN | Amgen Inc | Immunotherapy & Immuno-Oncology | $207.9b | $409.12 | +1.5% | 1.0M |
 GILD | Gilead Sciences Inc | Cell & Gene Therapy for Cancer | $161.7b | $133.19 | +1.7% | 6.2M |
 BMY | Bristol-Myers Squibb Co. | Immunotherapy & Immuno-Oncology | $133.4b | $64.02 | +0.7% | 5.0M |
 REGN | Regeneron Pharmaceuticals Inc | Immunotherapy & Immuno-Oncology | $78.2b | $777.31 | +1.6% | 462.9K |
 RVMD | Revolution Medicines, Inc. Common Stock | Targeted Therapy & Precision Oncology | $38.8b | $203.82 | +3.7% | 1.5M |
 NTRA | Natera, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $38.7b | $320.93 | +21.4% | 3.2M |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Immunotherapy & Immuno-Oncology | $25.3b | $57.86 | -0.8% | 2.7M |
 INCY | Incyte Genomics Inc | Targeted Therapy & Precision Oncology | $24.2b | $120.59 | +1.9% | 1.2M |
 MRNA | Moderna, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $22.0b | $59.35 | +9.8% | 6.0M |
 GH | Guardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $21.7b | $169.55 | +6.9% | 2.0M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Targeted Therapy & Precision Oncology | $15.9b | $256.63 | -0.1% | 588.1K |
 EXEL | Exelixis Inc | Targeted Therapy & Precision Oncology | $13.3b | $53.71 | +3.6% | 2.4M |
 CORT | Corcept Therapeutics Inc. | Targeted Therapy & Precision Oncology | $12.4b | $111.03 | +2.6% | 492.8K |
 HALO | Halozyme Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $9.8b | $101.25 | +20.2% | 7.3M |
 NUVL | Nuvalent, Inc. Class A Common Stock | Targeted Therapy & Precision Oncology | $9.8b | $123.96 | 0.0% | N/A |
 IBRX | ImmunityBio, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $7.5b | $7.59 | +4.3% | 8.5M |
 ACLX | Arcellx, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $6.7b | $115.06 | -0.0% | 16.1M |
 COGT | Cogent Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.7b | $42.42 | +1.4% | 1.5M |
 LNTH | Lantheus Holdings, Inc | Radiopharmaceuticals & ADCs | $6.5b | $100.35 | -0.1% | 1.6M |
 BLLN | BillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & Biomarkers | $6.4b | $93.67 | +1.7% | 1.4M |
 ERAS | Erasca, Inc. Common Stock | Targeted Therapy & Precision Oncology | $6.3b | $18.28 | +0.7% | 1.6M |
 CGON | CG Oncology, Inc. Common stock | Immunotherapy & Immuno-Oncology | $6.3b | $72.20 | +0.4% | 497.2K |
 TNGX | Tango Therapeutics, Inc. | Targeted Therapy & Precision Oncology | $4.4b | $26.98 | -6.7% | 2.9M |
 CAI | Caris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $4.4b | $22.63 | +13.8% | 7.8M |
 CELC | Celcuity Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.2b | $92.75 | -0.5% | 415.8K |
 RLAY | Relay Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $4.1b | $19.65 | +0.2% | 1.9M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.8b | $60.62 | +0.2% | 506.0K |
 VCYT | Veracyte, Inc. | Cancer Diagnostics & Biomarkers | $3.6b | $47.34 | +2.2% | 631.8K |
 ADPT | Adaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $3.6b | $24.77 | +5.6% | 2.3M |
 RCUS | Arcus Biosciences, Inc. | Immunotherapy & Immuno-Oncology | $3.5b | $29.24 | +1.0% | 883.4K |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $3.4b | $37.52 | +2.2% | 478.7K |
 GRAL | GRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $2.9b | $69.12 | +9.4% | 1.5M |
 IMNM | Immunome, Inc. | Targeted Therapy & Precision OncologyRadiopharmaceuticals & ADCs | $2.6b | $24.97 | -3.1% | 615.4K |
 NRIX | Nurix Therapeutics, Inc. Common stock | Targeted Therapy & Precision Oncology | $2.4b | $25.24 | +1.2% | 505.7K |
 NKTR | Nektar Therapeutics | Immunotherapy & Immuno-Oncology | $2.4b | $75.50 | +4.2% | 816.6K |
 PGEN | Precigen, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.4b | $7.17 | +4.5% | 5.4M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | Targeted Therapy & Precision Oncology | $2.2b | $21.52 | -0.0% | 3.0M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | Immunotherapy & Immuno-Oncology | $2.2b | $12.07 | +2.6% | 4.9M |
 NUVB | Nuvation Bio Inc. | Targeted Therapy & Precision Oncology | $2.1b | $6.55 | +7.7% | 5.1M |
 NEO | NeoGenomics, Inc. | Cancer Diagnostics & Biomarkers | $2.0b | $16.29 | +6.5% | 1.1M |
 BHVN | Biohaven Ltd. | Targeted Therapy & Precision Oncology | $2.0b | $14.54 | +1.7% | 875.5K |
 TYRA | Tyra Biosciences, Inc. Common Stock | Targeted Therapy & Precision Oncology | $1.9b | $26.50 | -1.9% | 694.2K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | Targeted Therapy & Precision Oncology | $1.9b | $47.98 | +2.9% | 892.5K |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | Cell & Gene Therapy for CancerImmunotherapy & Immuno-Oncology | $1.8b | $6.34 | +2.0% | 29.7M |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | Targeted Therapy & Precision Oncology | $1.8b | $29.94 | +0.1% | 161.6K |